Protagonist Therapeutics (PTGX) announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda (TAK) disclosed on January 31, 2024. Closing of the transaction was contingent on completion of review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States. Protagonist will receive the $300 million upfront payment associated with the transaction in the second quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PTGX:
- Protagonist Therapeutics announces presentation of data on JNJ-2113
- New Debt & Financing Risk for Protagonist Therapeutics Inc – What’s the Latest?
- 3 Best Stocks to Buy Now, 2/2/2024, According to Top Analysts
- Protagonist Therapeutics Inks Deal with Takeda on Rusfertide
- Protagonist Therapeutics, Takeda enter into license agreement for Rusfertide